| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A Crooked Smile
|
Denny, Victoria
|
|
|
18 |
4 |
p. 433
|
article
|
| 2 |
Anal cancer: from an orphan disease to a curable malignancy?
|
Cascinu, Stefano
|
|
|
18 |
4 |
p. 415-416
|
article
|
| 3 |
A second chance for success with BRAF and MEK inhibitors in melanoma
|
Paulson, Kelly G
|
|
|
18 |
4 |
p. 418-419
|
article
|
| 4 |
A step forward for patients with NRAS-mutant melanoma
|
Postow, Michael A
|
|
|
18 |
4 |
p. 414-415
|
article
|
| 5 |
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
|
Dummer, Reinhard
|
|
|
18 |
4 |
p. 435-445
|
article
|
| 6 |
Blinatumomab significantly improves overall survival
|
Burki, Talha Khan
|
|
|
18 |
4 |
p. e203
|
article
|
| 7 |
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial
|
Ladenstein, Ruth
|
|
|
18 |
4 |
p. 500-514
|
article
|
| 8 |
Cancer incidence in Canadian prisoners
|
Burki, Talha Khan
|
|
|
18 |
4 |
p. e200
|
article
|
| 9 |
Carcinoid syndrome in neuroendocrine tumors: a prognostic effect?
|
Ducreux, Michel
|
|
|
18 |
4 |
p. 426-428
|
article
|
| 10 |
Clinical endpoints in trials of chemoradiation for patients with anal cancer
|
Glynne-Jones, Robert
|
|
|
18 |
4 |
p. e218-e227
|
article
|
| 11 |
Clofarabine-based consolidation therapy in AML
|
Brower, Vicki
|
|
|
18 |
4 |
p. e201
|
article
|
| 12 |
Colorectal cancer: a disease of the young?
|
The Lancet Oncology,
|
|
|
18 |
4 |
p. 413
|
article
|
| 13 |
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF V600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial
|
Schreuer, Max
|
|
|
18 |
4 |
p. 464-472
|
article
|
| 14 |
Common genetic variation and risk of gallbladder cancer in India: a case-control genome-wide association study
|
Mhatre, Sharayu
|
|
|
18 |
4 |
p. 535-544
|
article
|
| 15 |
Correction to Lancet Oncol 2017; 18: 347–56
|
|
|
|
18 |
4 |
p. e196
|
article
|
| 16 |
Correction to Lancet Oncol 2017; 18: e142
|
|
|
|
18 |
4 |
p. e196
|
article
|
| 17 |
Correction to Lancet Oncol 2017; 18: e81, e82, e86
|
|
|
|
18 |
4 |
p. e196
|
article
|
| 18 |
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
|
Chi, Kim N
|
|
|
18 |
4 |
p. 473-485
|
article
|
| 19 |
Dev Diaries
|
Kinsey, Caroline
|
|
|
18 |
4 |
p. 434
|
article
|
| 20 |
DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial
|
Nielsen, Stine Nygaard
|
|
|
18 |
4 |
p. 515-524
|
article
|
| 21 |
Drug development in prostate cancer: time to embrace RECIST?
|
Sonpavde, Guru
|
|
|
18 |
4 |
p. 419-421
|
article
|
| 22 |
Fasting: starving cancer
|
Cathcart, Paul
|
|
|
18 |
4 |
p. 431
|
article
|
| 23 |
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study
|
Halperin, Daniel M
|
|
|
18 |
4 |
p. 525-534
|
article
|
| 24 |
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
|
Llombart-Cussac, Antonio
|
|
|
18 |
4 |
p. 545-554
|
article
|
| 25 |
Inflammatory breast cancer: a proposed conceptual shift in the UICC–AJCC TNM staging system
|
Fouad, Tamer M
|
|
|
18 |
4 |
p. e228-e232
|
article
|
| 26 |
Intravenacaval invasion of classical Hodgkin lymphoma detected with 18F-fluorodeoxyglucose (18F-FDG) PET–MRI
|
Makita, Shinichi
|
|
|
18 |
4 |
p. e233
|
article
|
| 27 |
Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer
|
Mathew, Aju
|
|
|
18 |
4 |
p. 428-429
|
article
|
| 28 |
Loving, supporting, and caring for the cancer patient
|
Mariotti, Laura
|
|
|
18 |
4 |
p. 433
|
article
|
| 29 |
Mercaptopurine in childhood acute lymphoblastic leukaemia
|
Gaynon, Paul S
|
|
|
18 |
4 |
p. 425-426
|
article
|
| 30 |
Mum's List
|
Kennedy, Anna
|
|
|
18 |
4 |
p. 432
|
article
|
| 31 |
Nivolumab activity in relapsed Hodgkin's lymphoma
|
Das, Manjulika
|
|
|
18 |
4 |
p. e205
|
article
|
| 32 |
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
|
Morris, Van K
|
|
|
18 |
4 |
p. 446-453
|
article
|
| 33 |
Open letter to Lady Scotland
|
Weller, David
|
|
|
18 |
4 |
p. e194
|
article
|
| 34 |
Open letter to Lady Scotland – Author's reply
|
Nurse, Joanna
|
|
|
18 |
4 |
p. e195
|
article
|
| 35 |
Optimising haemopoietic cell transplantation
|
Venkatesan, Priya
|
|
|
18 |
4 |
p. e198
|
article
|
| 36 |
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer
|
Yan, Weigang
|
|
|
18 |
4 |
p. e187
|
article
|
| 37 |
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer – Authors' reply
|
Azzouzi, Abdel-Rahmène
|
|
|
18 |
4 |
p. e188
|
article
|
| 38 |
Pembrolizumab as second-line treatment for urothelial cancer
|
Mitchell, Fiona
|
|
|
18 |
4 |
p. e197
|
article
|
| 39 |
Pravastatin has no advantage in small-cell lung cancer
|
Brower, Vicki
|
|
|
18 |
4 |
p. e204
|
article
|
| 40 |
Predicting outcomes after a positive interim FDG-PET scan in advanced Hodgkin's lymphoma
|
Crump, Michael
|
|
|
18 |
4 |
p. 416-418
|
article
|
| 41 |
Preventable cancer: off-limits for Commonwealth meeting?
|
The Lancet Oncology,
|
|
|
18 |
4 |
p. 413
|
article
|
| 42 |
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
|
Borchmann, Peter
|
|
|
18 |
4 |
p. 454-463
|
article
|
| 43 |
Refining megatherapy, improving outcome in neuroblastoma
|
Bagatell, Rochelle
|
|
|
18 |
4 |
p. 423-424
|
article
|
| 44 |
Results from the BRIOS randomised trial
|
Kovacs, Tibor
|
|
|
18 |
4 |
p. e190
|
article
|
| 45 |
Results from the BRIOS randomised trial
|
Potter, Shelley
|
|
|
18 |
4 |
p. e189
|
article
|
| 46 |
Results from the BRIOS randomised trial – Authors' reply
|
Mullender, Margriet G
|
|
|
18 |
4 |
p. e191
|
article
|
| 47 |
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
|
Cavo, Michele
|
|
|
18 |
4 |
p. e206-e217
|
article
|
| 48 |
Rushing will not help to choose the best combination
|
Addeo, Alfredo
|
|
|
18 |
4 |
p. e186
|
article
|
| 49 |
Scalp cooling and hair loss during breast cancer chemotherapy
|
Brower, Vicki
|
|
|
18 |
4 |
p. e199
|
article
|
| 50 |
Service review: improving breast cancer care in Tanzania
|
Mayor, Susan
|
|
|
18 |
4 |
p. 430
|
article
|
| 51 |
Stereotactic body radiotherapy for patients with hepatocellular carcinoma and intermediate grade cirrhosis
|
Nabavizadeh, Nima
|
|
|
18 |
4 |
p. e192
|
article
|
| 52 |
Stereotactic body radiotherapy for patients with hepatocellular carcinoma and intermediate grade cirrhosis – Authors' reply
|
Granito, Alessandro
|
|
|
18 |
4 |
p. e193
|
article
|
| 53 |
Targeted therapy of pancreatic cancer: biomarkers are needed
|
Kleeff, Jörg
|
|
|
18 |
4 |
p. 421-422
|
article
|
| 54 |
Treating chemotherapy-induced peripheral neuropathy
|
Das, Manjulika
|
|
|
18 |
4 |
p. e202
|
article
|
| 55 |
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
|
Middleton, Gary
|
|
|
18 |
4 |
p. 486-499
|
article
|
Journal description